metronidazole has been researched along with rabeprazole in 85 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.18) | 18.2507 |
| 2000's | 32 (37.65) | 29.6817 |
| 2010's | 46 (54.12) | 24.3611 |
| 2020's | 6 (7.06) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Castillo, R; Hernández-Campos, A; Hernández-Luis, F; Pérez-Villanueva, J; Romo-Mancillas, A; Yépez-Mulia, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bala, V; Chhonker, YS | 1 |
| Atherton, JC; Cockayne, A; Hawkey, CJ; Jenkins, D; Knifton, A; Stack, WA; Thirlwell, D | 1 |
| Iida, N; Kurosawa, A; Miwa, H; Nagahara, A; Ogawa, K; Ohkura, R; Sato, N | 1 |
| Kurosawa, A; Miwa, H; Nagahara, A; Ohkura, R; Sato, N; Yamada, T | 1 |
| Fujioka, T; Kagawa, J; Kodama, M; Murakami, K; Okimoto, T; Satoh, R | 1 |
| Hojo, M; Miwa, H; Nagahara, A; Ohkura, R; Sato, K; Sato, N; Yamada, T | 1 |
| Esaki, M; Fukuda, T; Kurahara, K; Kusano, Y; Matsumoto, T; Nakamura, S | 1 |
| Fujioka, T; Kodama, M; Murakami, K; Nasu, M; Okimoto, T; Sato, R | 1 |
| Fu, HY; Kawano, S; Tanimura, H | 1 |
| Ohkusa, T; Sato, N | 1 |
| Takahashi, S; Tokunaga, K | 1 |
| Ishitobi, H; Murakami, K; Nasu, M; Okimoto, T; Sato, R | 1 |
| Calvet, X; Gisbert, JP; Vallve, M; Vergara, M | 1 |
| Fujioka, T; Kagawa, J; Kodama, M; Murakami, K; Nasu, M; Okimoto, T; Sato, R | 1 |
| Enjoji, A; Fujimoto, C; Furusu, H; Hirakata, Y; Inoue, K; Isomoto, H; Kohno, S; Mizuta, Y; Murase, K; Murata, I; Omagari, K; Shimada, S; Yamakawa, M | 1 |
| Bilardi, C; Dulbecco, P; Gambaro, C; Iiritano, E; Mansia, C; Savarino, V; Usai, P; Vigneri, S; Zentilin, P | 1 |
| Abudayyeh, S; Belson, G; Dore, MP; El-Zimaity, HM; Graham, DY; Osato, MS | 1 |
| Iinuma, K; Kato, S; Konno, M; Maisawa, S; Nakayama, Y; Shimizu, T; Tajiri, H; Toyoda, S; Yoshimura, N | 1 |
| Chang, FY; Chen, CY; Lee, SD; Lu, CL; Lu, RH; Luo, JC | 1 |
| Chan, AO; Chan, CK; Cheung, KL; Fung, FM; Ho, VY; Huang, J; Hui, CK; Lai, KC; Lam, SK; Tong, TS; Wong, BC; Wong, WM; Xia, HH | 1 |
| Botta, F; Fumagalli, A; Giannini, EG; Malfatti, F; Mamone, M; Polegato, S; Savarino, V; Testa, E; Testa, R | 1 |
| Fujioka, T | 1 |
| Fujioka, T; Murakami, K; Okimoto, T | 1 |
| Furuta, T; Nakamura, A; Shirai, N; Sugimoto, M | 1 |
| Asaka, M; Kato, M; Nakagawa, M; Nakagawa, S; Shimizu, Y | 1 |
| Abe, T; Arita, T; Fujioka, T; Kodama, M; Murakami, K; Nasu, M; Okimoto, T; Sato, R; Sato, S; Watanabe, K | 1 |
| Hirakawa, K; Ishikawa, T; Katsuragi, K; Maeda, K; Mino, A; Ohira, M; Onoda, N; Sawada, T; Wakasa, K | 1 |
| Furuta, T; Hishida, A; Ikuma, M; Ishizaki, T; Kajimura, M; Kodaira, C; Nishino, M; Ohashi, K; Shirai, N; Sugimoto, M | 1 |
| Mahachai, V; Thong-Ngam, D | 1 |
| Fujioka, T; Kodama, M; Murakami, K; Okimoto, T; Sato, R; Watanabe, K | 1 |
| Hibi, T; Iwasaki, E; Masaoka, T; Nakagawa, I; Nishizawa, T; Suzuki, H | 1 |
| García, A; González, CL; Soto, A | 1 |
| Hwang, JH; Jeong, SH; Jung, HC; Kim, JJ; Kim, JW; Kim, N; Kwon, JH; Lee, DH; Lee, JW; Lee, SH; Park, YS; Song, BJ; Song, IS | 1 |
| Hori, K; Matsumoto, T; Miwa, H | 1 |
| Goto, Y; Hamajima, N; Inoue, S; Kamiya, Y; Kawai, S; Kondo, T; Kurata, M; Tamura, T | 1 |
| Cho, HJ; Cho, YR; Hwang, JH; Jeoung, SH; Jung, HC; Kim, JW; Kim, N; Lee, DH; Lee, SH; Oh, HS; Park, YS; Seo, JY; Shin, CM; Song, IS | 1 |
| Dobashi, Y; Fukunishi, M; Matsumoto, S; Miyatani, H; Takamatsu, T; Ugajin, T; Yoshida, Y | 1 |
| Cho, KB; Jeon, SW; Jung, JT; Jung, MK; Kim, ES; Kim, EY; Kim, KO; Kwon, JG; Lee, JH; Lee, SH; Park, HG; Park, KS; Seo, HE; Yang, CH | 1 |
| Ando, T; Fujinami, H; Hosokawa, A; Kudo, T; Murakami, J; Nishikawa, J; Ogawa, K; Orihara, T; Sugiyama, T; Takahara, T | 1 |
| Amornsawadwattana, S; Kongchayanun, C; Mahachai, V; Pornthisarn, B; Vilaichone, RK | 1 |
| Arai, T; Furuhata, Y; Iinuma, N; Sakata, Y; Sugizaki, K; Suzuki, H | 1 |
| Choi, C; Hwang, JH; Jang, ES; Jeong, SH; Jo, HJ; Jung, HC; Kim, JW; Kim, N; Lee, DH; Lee, SH; Lee, ST; Lim, JH; Park, YS; Shin, CM; Song, Is | 1 |
| Cheung, DY; Chung, WC; Jun, EJ; Kim, BW; Kim, JI; Kim, JK; Kim, SS; Kim, TH; Lee, HJ; Oh, JH; Park, SH | 1 |
| Furuta, T; Ichikawa, H; Kodaira, C; Nishino, M; Osawa, S; Sahara, S; Sugimoto, K; Sugimoto, M; Umemura, K; Uotani, T; Watanabe, H; Yamada, T; Yamade, M | 1 |
| Atasoy, P; Güliter, S; Kalkan, IH; Sapmaz, F | 1 |
| Chang, HJ; Geary, J; Goodman, KJ; Keelan, M; Morse, AL; Morse, JW; Munday, R; Sander, Vv | 1 |
| Furuta, T; Ichikawa, H; Sahara, S; Sugimoto, K; Sugimoto, M; Uotani, T; Yamade, M | 1 |
| Harada, N; Hosoda, Y; Inoue, S; Katayama, S; Kimura, T; Kuwai, T; Maekawa, T; Masuda, E; Miyabayashi, H; Nishizawa, T; Nishizawa, Y; Ohta, H; Saito, H; Suzuki, H; Takahashi, M; Toyokawa, T; Watanabe, N; Yamashita, H; Yoshinaga, M; Yoshio, T | 1 |
| Hwang, JH; Jang, ES; Jeoung, SH; Jung, HC; Kang, KK; Kim, JW; Kim, N; Lee, DH; Oh, DH; Park, YS; Shin, CM; Yoon, H | 1 |
| Cho, Y; Chung, KH; Hwang, JH; Jeong, SH; Jin, E; Kim, JW; Kim, N; Lee, DH; Seo, JY; Shin, CM | 1 |
| Hong, SN; Kim, JJ; Lee, H; Lee, JH; Lee, YC; Min, BH; Rhee, PL | 1 |
| Cheung, DY; Chung, WC; Jun, EJ; Kim, BW; Kim, JI; Kim, SS; Lee, HJ; Lee, JS; Oh, JH | 1 |
| Al-Adhba, HS; Ben Chaabane, N | 1 |
| Aktaş, B; Başyiğit, S; Kefeli, A; Nazlıgül, Y; Uzman, M; Yeniova, AÖ | 1 |
| Akkan, T; Aktaş, B; Atbaşı, ST; Başyiğit, S; Nazlıgül, Y; Şimşek, G; Uzman, M; Yılmaz, B; Yüksel, O | 1 |
| Hwang, JJ; Kim, N; Lee, AR; Lee, DH; Park, YS; Shin, CM; Yoon, H | 2 |
| Abdel-Hay, MH; Belal, TS; Mahgoub, AA; Sabry, SM | 1 |
| Furuta, T; Ichikawa, H; Kagami, T; Sahara, S; Sugimoto, M; Uotani, T | 1 |
| Altun, B; Ozturk, K | 1 |
| Bair, MJ; Hsu, PI; Hsu, WH; Hu, CT; Hu, HM; Jheng, GH; Kuo, CH; Kuo, FC; Liu, CJ; Shih, HY; Wu, DC; Wu, IC; Wu, MC | 1 |
| Gisbert, JP; Molina-Infante, J | 1 |
| Sugimoto, M | 1 |
| Hwang, JH; Jang, ES; Jeong, SH; Kim, J; Kim, JW; Kim, N; Lee, DH; Park, YS; Shin, CM; Yoon, H | 1 |
| Hwang, JJ; Kim, N; Lee, DH; Park, YS; Shin, CM; Yoon, H | 1 |
| Chen, KY; Lee, HC; Lin, CL; Lin, TJ; Wang, CK; Wu, DC | 1 |
| Aslan, M; Basyigit, S; Kefeli, A; Kefeli, TT; Tanas, O; Yeniova, AO | 1 |
| Andoh, A; Ban, H; Furuta, T; Ichikawa, H; Kagami, T; Otsuka, T; Sahara, S; Sugimoto, M | 1 |
| Bhanthumkomol, P; Chonprasertsuk, S; Mahachai, V; Phiphatpatthamaamphan, K; Pornthisarn, B; Siramolpiwat, S; Tangaroonsanti, A; Vilaichone, RK | 1 |
| Kajihara, Y; Mizuki, I; Shimoyama, T | 1 |
| Choi, YJ; Kang, JB; Kim, N; Kwon, S; Lee, DH; Park, YS; Shin, CM; Yoon, H | 1 |
| Robotis, J; Rokkas, T; Tsiodras, S | 1 |
| Irie, K; Kaneko, H; Kondo, M; Maeda, S; Sasaki, T; Shibata, W; Sue, S | 1 |
| Baik, GH; Bang, CS; Choi, JH; Hong, JT; Jeong, HM; Kang, HS; Kim, DJ; Lee, JJ; Lim, H; Shin, SP; Shin, WG; Soh, JS; Suk, KT; Yang, YJ | 1 |
| Kiguchi, T; Kono, Y; Kusumoto, C; Okada, H | 1 |
| Pan, L; Tang, G; Tang, Y; Wei, Z; Zhou, S; Zhu, H | 1 |
| Fukuda, K; Fukuda, M; Hirashita, Y; Kawahara, Y; Kodama, M; Kudo, Y; Matsunari, O; Mizukami, K; Murakami, K; Ogawa, R; Okamoto, K; Okimoto, T; Wada, Y | 1 |
| Abbondio, M; Bibbò, S; Dore, MP; Loria, M; Niolu, C; Pes, GM; Sau, R; Tanca, A; Uzzau, S | 1 |
| Jang, JS; Jee, SR; Jung, K; Kim, GH; Kim, SJ; Koh, M; Lee, J; Lee, MW; Park, MI | 1 |
13 review(s) available for metronidazole and rabeprazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Recent developments in anti-Trichomonas research: An update review.
Topics: Antiparasitic Agents; Biological Products; Dose-Response Relationship, Drug; Humans; Molecular Structure; Parasitic Sensitivity Tests; Structure-Activity Relationship; Trichomonas; Trichomonas Infections | 2018 |
[Selection of antibiotics and planning of eradication for H. pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole | 2001 |
[Dual therapy for Helicobacter pylori resistance to anti microbial agents].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Clinical Trials as Topic; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Humans; Metronidazole; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole | 2002 |
[Proton pump inhibitor-based quadruple therapy regimen for Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Bismuth; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Tetracycline | 2002 |
[Second line treatment regimen of PPI + AMPC + MNZ for patients with clarithromycin-resistant Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Failure | 2002 |
[Minocycline-containing eradication therapy for patients with clarithromycin-resistant Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Minocycline; Omeprazole; Rabeprazole; Treatment Failure | 2002 |
Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Pantoprazole; Penicillins; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; Treatment Outcome | 2002 |
[Establishment of 2nd line treatment regimen for H. pylori infection--future prospect for the application for national health insurance system in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Metronidazole; National Health Programs; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2005 |
[Second-line eradication therapy for H. pylori infection--PPI+AMPC+MNZ triple therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2005 |
[High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Treatment Failure | 2005 |
[Investigation about 3rd line eradication of H. pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ampicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Treatment Failure | 2005 |
Gastrointestinal: Rapid emergence of double-expressor lymphoma after Helicobacter pylori eradication therapy.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Endoscopy, Digestive System; Follow-Up Studies; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Metronidazole; Middle Aged; Rabeprazole; Stomach Neoplasms | 2021 |
43 trial(s) available for metronidazole and rabeprazole
| Article | Year |
|---|---|
Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Proton-Translocating ATPases; Rabeprazole; Time Factors; Treatment Outcome | 1998 |
Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Rabeprazole; Treatment Outcome | 2000 |
Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Carbon Isotopes; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Rabeprazole; Treatment Outcome | 2001 |
Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Resistance, Bacterial; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors; Rabeprazole | 2003 |
High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Rabeprazole; Treatment Outcome | 2003 |
Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Pilot Projects; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2003 |
Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Patient Compliance; Pilot Projects; Prospective Studies; Proton-Translocating ATPases; Rabeprazole; Salicylates; Tetracycline; Treatment Outcome | 2004 |
Response of blood endothelin-1 and nitric oxide activity in duodenal ulcer patients undergoing Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Biomarkers; Drug Therapy, Combination; Duodenal Ulcer; Endothelin-1; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Nitrates; Nitric Oxide; Nitrites; Omeprazole; Rabeprazole | 2005 |
Low-dose rabeprazole, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Biopsy; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyspepsia; Endoscopy, Gastrointestinal; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Prevalence; Proton-Translocating ATPases; Pyloric Antrum; Rabeprazole; Retrospective Studies; Treatment Outcome | 2005 |
Influence of 1-week Helicobacter pylori eradication therapy with rabeprazole, clarithromycin, and metronidazole on 13C-aminopyrine breath test.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aminopyrine; Anti-Bacterial Agents; Anti-Infective Agents; Benzimidazoles; Breath Tests; Carbon Isotopes; Clarithromycin; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Liver; Liver Function Tests; Male; Metronidazole; Middle Aged; Omeprazole; Rabeprazole | 2005 |
Effectiveness of minocycline-based triple therapy for eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Minocycline; Omeprazole; Peptic Ulcer; Rabeprazole; Treatment Outcome | 2006 |
Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Middle Aged; Prospective Studies; Rabeprazole | 2007 |
Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Retreatment; Treatment Outcome | 2008 |
Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Infective Agents; Clarithromycin; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Gatifloxacin; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2008 |
Efficacy of 2-week, second-line Helicobacter pylori eradication therapy using rabeprazole, amoxicillin, and metronidazole for the Japanese population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Asian People; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Metronidazole; Middle Aged; Prospective Studies; Rabeprazole; Treatment Outcome; Young Adult | 2011 |
Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Breath Tests; Chi-Square Distribution; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Medication Adherence; Metronidazole; Middle Aged; Proton Pump Inhibitors; Rabeprazole; Republic of Korea | 2012 |
Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer; Rabeprazole; Republic of Korea; Time Factors; Treatment Outcome | 2012 |
Comparison of lafutidine and rabeprazole in 7-day second-line amoxicillin- and metronidazole-containing triple therapy for Helicobacter pylori: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetamides; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pilot Projects; Piperidines; Pyridines; Rabeprazole; Time Factors; Young Adult | 2012 |
Pilot studies to identify the optimum duration of concomitant Helicobacter pylori eradication therapy in Thailand.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pilot Projects; Prospective Studies; Rabeprazole; Thailand; Time Factors; Young Adult | 2012 |
A multicenter prospective observational study of triple therapy with rabeprazole, amoxicillin and metronidazole for Helicobacter pylori in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2012 |
Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pilot Projects; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome; Urea | 2013 |
Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Point Mutation; Polymerase Chain Reaction; Proton Pump Inhibitors; Rabeprazole; RNA, Ribosomal, 23S; Treatment Outcome; Young Adult | 2013 |
Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Fluoroquinolones; Gastritis; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Time Factors; Treatment Outcome | 2014 |
Comparison of Helicobacter pylori eradication rates of standard 14-day quadruple treatment and novel modified 10-day, 12-day and 14-day sequential treatments.
Topics: Adult; Anti-Infective Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Remission Induction; Tetracycline; Time Factors; Turkey | 2014 |
A randomized controlled trial comparing sequential with triple therapy for Helicobacter pylori in an Aboriginal community in the Canadian North.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Inuit; Male; Medication Adherence; Metronidazole; Middle Aged; Northwest Territories; Proton Pump Inhibitors; Rabeprazole | 2013 |
Clarithromycin Versus Metronidazole as First-line Helicobacter pylori Eradication: A Multicenter, Prospective, Randomized Controlled Study in Japan.
Topics: Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Metronidazole; Middle Aged; Prospective Studies; Rabeprazole; Urea | 2015 |
Efficacy of hybrid therapy as first-line regimen for Helicobacter pylori infection compared with sequential therapy.
Topics: Aged; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Rabeprazole; Treatment Outcome | 2014 |
Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Rabeprazole; Republic of Korea; Treatment Outcome; Urea | 2015 |
Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Metronidazole; Middle Aged; Predictive Value of Tests; Proton Pump Inhibitors; Rabeprazole; Republic of Korea; Stomach Ulcer; Time Factors; Treatment Outcome | 2015 |
Ciprofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: A randomized trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Ciprofloxacin; Clarithromycin; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Humans; Male; Metronidazole; Middle Aged; Rabeprazole; Treatment Outcome; Young Adult | 2015 |
Different treatment choice for first-line treatment of Helicobacter pylori in an area with a high antibiotic resistance.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Rabeprazole; Turkey | 2014 |
The impact of amalgam dental fillings on the frequency of Helicobacter pylori infection and H. pylori eradication rates in patients treated with concomitant, quadruple, and levofloxacin-based therapies.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Dental Amalgam; Dental Restoration, Permanent; Disease Eradication; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Levofloxacin; Male; Metronidazole; Middle Aged; Outpatients; Prospective Studies; Rabeprazole; Tetracycline; Treatment Outcome; Turkey; Urea | 2015 |
Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease.
Topics: Aged; Anti-Bacterial Agents; Biopsy; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Medication Adherence; Metronidazole; Middle Aged; Moxifloxacin; Multivariate Analysis; Odds Ratio; Pilot Projects; Predictive Value of Tests; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Republic of Korea; Stomach Diseases; Time Factors; Treatment Outcome | 2015 |
Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection.
Topics: Adult; Aged; Amoxicillin; Bismuth; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Rabeprazole; Tetracycline | 2015 |
Effects of N-acetylcysteine on First-Line Sequential Therapy for Helicobacter pylori Infection: A Randomized Controlled Pilot Trial.
Topics: Acetylcysteine; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Metronidazole; Middle Aged; Pilot Projects; Rabeprazole; Treatment Outcome | 2016 |
Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication.
Topics: Aged; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Medication Adherence; Metronidazole; Middle Aged; Moxifloxacin; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Republic of Korea; Time Factors; Treatment Outcome | 2015 |
Hybrid vs sequential therapy for eradication of Helicobacter pylori in Taiwan: A prospective randomized trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Taiwan; Time Factors; Treatment Outcome | 2015 |
Comparison of three different regimens against Helicobacter pylori as a first-line treatment: A randomized clinical trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Biopsy; Bismuth; Clarithromycin; Cross-Over Studies; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Gastric Mucosa; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Potassium Citrate; Prospective Studies; Rabeprazole; Tetracycline; Time Factors; Young Adult | 2016 |
Effect of IL-1 Polymorphisms, CYP2C19 Genotype and Antibiotic Resistance on Helicobacter pylori Eradication Comparing Between 10-day Sequential Therapy and 14-day Standard Triple Therapy with Four-Times-Daily-Dosing of Amoxicillin in Thailand: a Prospecti
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Interleukin-1; Male; Metronidazole; Middle Aged; Polymorphism, Genetic; Prognosis; Prospective Studies; Rabeprazole; Young Adult | 2016 |
Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Gastritis; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Sulfonamides; Treatment Failure; Treatment Outcome | 2019 |
Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Organometallic Compounds; Patient Compliance; Penicillin Resistance; Rabeprazole; Tetracycline; Tetracycline Resistance | 2020 |
Metagenomic Changes of Gut Microbiota following Treatment of
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Limosilactobacillus reuteri; Metronidazole; Proton Pump Inhibitors; Rabeprazole; RNA, Ribosomal, 16S; Tetracycline; Treatment Outcome | 2022 |
A randomized controlled trial to compare Helicobacter pylori eradication rates between the empirical concomitant therapy and tailored therapy based on 23S rRNA point mutations.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Point Mutation; Proton Pump Inhibitors; Rabeprazole; RNA, Ribosomal, 23S | 2022 |
29 other study(ies) available for metronidazole and rabeprazole
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Antiprotozoal activity of proton-pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antiprotozoal Agents; Drug Design; Entamoeba histolytica; Giardia lamblia; Humans; Lansoprazole; Omeprazole; Pantoprazole; Parasitic Diseases; Proton Pump Inhibitors; Rabeprazole; Trichomonas vaginalis | 2011 |
Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Recurrence; Retrospective Studies; Treatment Failure | 2001 |
Duodenal mucosa-associated lymphoid tissue lymphoma treated by eradication of Helicobacter pylori: report of 2 cases including EUS findings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Benzimidazoles; Biopsy, Needle; Clarithromycin; Drug Therapy, Combination; Duodenal Neoplasms; Duodenoscopy; Endosonography; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Mucosa; Lymphoma, B-Cell, Marginal Zone; Metronidazole; Middle Aged; Omeprazole; Rabeprazole; Treatment Outcome | 2001 |
Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies | 2002 |
Results of triple eradication therapy in Japanese children: a retrospective multicenter study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Child; Child, Preschool; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Humans; Infant; Lansoprazole; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Sulfoxides | 2004 |
Efficacy of Helicobacter pylori eradication on the chronic mucosal inflammation of the remnant stomach after distal gastrectomy for early gastric cancer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Therapy, Combination; Endoscopy, Digestive System; Female; Gastrectomy; Gastric Mucosa; Gastric Stump; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Rabeprazole; Stomach Neoplasms | 2005 |
14-day quadruple therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure in Thailand.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Chi-Square Distribution; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Rabeprazole; Ranitidine; Tetracycline; Treatment Failure | 2006 |
In vitro antagonism of rabeprazole and metronidazole upon clinical isolates of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Drug Synergism; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Microbial Sensitivity Tests; Rabeprazole | 2009 |
Ten-day sequential therapy as first-line treatment for Helicobacter pylori infection in Korea: a retrospective study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Female; Helicobacter Infections; Helicobacter pylori; Humans; Korea; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Time Factors; Treatment Outcome; Urea | 2010 |
Improvements in Helicobacter pylori eradication rates through clinical CYP2C19 genotyping.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Metronidazole; Middle Aged; Pharmacogenetics; Proton Pump Inhibitors; Rabeprazole; Young Adult | 2011 |
Regression of multiple duodenal hyperplastic polyps following Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Breath Tests; Clarithromycin; Drug Therapy, Combination; Duodenal Diseases; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Polyps; Metronidazole; Middle Aged; Rabeprazole | 2011 |
Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2014 |
The efficacy of moxifloxacin-containing triple therapy after standard triple, sequential, or concomitant therapy failure for Helicobacter pylori eradication in Korea.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Cohort Studies; Drug Therapy, Combination; Female; Fluoroquinolones; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Moxifloxacin; Organometallic Compounds; Peptic Ulcer; Rabeprazole; Republic of Korea; Retrospective Studies; Salvage Therapy; Stomach; Tetracycline; Treatment Failure; Treatment Outcome; Urea | 2014 |
Development and validation of HPLC-DAD method for the simultaneous determination of amoxicillin, metronidazole and rabeprazole sodium. Application to spiked simulated intestinal fluid samples.
Topics: Amoxicillin; Anti-Bacterial Agents; Body Fluids; Calibration; Chromatography, High Pressure Liquid; Drug Stability; Humans; Metronidazole; Proton Pump Inhibitors; Rabeprazole; Reproducibility of Results | 2015 |
High Helicobacter pylori cure rate with sitafloxacin-based triple therapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Breath Tests; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Rabeprazole | 2015 |
Efficiency of Moxifloxacin in the Treatment of Helicobacter pylori Infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Female; Fluoroquinolones; Helicobacter Infections; Humans; Male; Metronidazole; Organometallic Compounds; Rabeprazole; Tetracycline | 2015 |
Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Breath Tests; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Medical Records; Medication Adherence; Metronidazole; Middle Aged; Organometallic Compounds; Proton Pump Inhibitors; Rabeprazole; Remission Induction; Retrospective Studies; Tetracycline; Time Factors; Treatment Outcome | 2015 |
Letter: sitafloxacin for H. pylori infection in Japan: considerations on resistance rates, generalisability and its place in the therapeutic algorithm.
Topics: Female; Fluoroquinolones; Helicobacter Infections; Humans; Male; Metronidazole; Rabeprazole | 2015 |
Letter: sitafloxacin for H. pylori infection in Japan: considerations on resistance rates, generalisability and its place in the therapeutic algorithm - author's reply.
Topics: Female; Fluoroquinolones; Helicobacter Infections; Humans; Male; Metronidazole; Rabeprazole | 2015 |
Four-times-daily Dosing of Rabeprazole with Sitafloxacin, High-Dose Amoxicillin, or Both for Metronidazole-Resistant Infection with Helicobacter pylori in Japan.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Resistance, Bacterial; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Hospitals, University; Humans; Japan; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Treatment Outcome | 2017 |
Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Retrospective Studies; Sulfonamides | 2017 |
[The Efficacy of Moxifloxacin-containing Triple Therapy after Hybrid Therapy Failure in
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Moxifloxacin; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Topoisomerase II Inhibitors; Treatment Failure; Treatment Outcome | 2017 |
Helicobacter pylori eradication may successfully treat primary cutaneous follicle center lymphoma.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Doxycycline; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lymphoma, B-Cell; Metronidazole; Middle Aged; Organometallic Compounds; Rabeprazole; Salicylates | 2018 |
Clinical factors associated with initial Helicobacter pylori eradication therapy: a retrospective study in China.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies | 2020 |
Gastric mucosal changes, and sex differences therein, after Helicobacter pylori eradication: A long-term prospective follow-up study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Atrophy; Clarithromycin; Female; Follow-Up Studies; Gastric Mucosa; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metaplasia; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Sex Factors; Young Adult | 2021 |